Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51655 | 0.89 | SIGMAR1 (0.34) | CYP3A4MEN1TMEM97SIGMAR1 | |
| SCHEMBL51628 | 0.84 | HTR6 (0.33) | CYP3A4MEN1KMT2AALDH1A1ESR2 | |
| SCHEMBL51609 | 0.82 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL52067 | 0.80 | HTR7 (0.35) | SIGMAR1 | |
| SCHEMBL16063012 | 0.74 | SIGMAR1 (0.47) | MEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL52439 | 0.74 | L3MBTL1 (0.36) | CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL13678422 | 0.71 | TMEM97 (0.49) | MEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL52657 | 0.70 | ALDH1A1 (0.41) | ALDH1A1SIGMAR1 | |
| SCHEMBL51395 | 0.69 | ALDH1A1 (0.43) | ALDH1A1SIGMAR1 | |
| SCHEMBL52616 | 0.68 | ALDH1A1 (0.45) | ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129531-B2 | Using an isoquinoline compound; alkylation of benzonitrile; reduction ofnitrile to an amine; cyclization | BASF AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| EP-1891192-B1 | ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY | PROCTER & GAMBLE (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090149366-A1 | ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY | MIRACLE GREGORY SCOT | 2009-06-11 | — | — | US | disclosed |
| US-7504371-B2 | Organic catalyst with enhanced enzyme compatibility | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080214819-A1 | Process of Producing Bleach Boosters | BASF AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1896561-A2 | PROCESS OF PRODUCING BLEACH BOOSTERS | BASF SE (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070197421-A1 | Organic catalyst with enhanced enzyme compatibility | PROCTER & GAMBLE COMPANY, THE | 2007-08-23 | — | — | US | disclosed |
| US-20060287210-A1 | Organic catalyst with enhanced enzyme compatibility | PROCTER & GAMBLE COMPANY, THE | 2006-12-21 | — | — | US | disclosed |
| WO-2006134144-A2 | PROCESS OF PRODUCING BLEACH BOOSTERS | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214819-A1 | Process of Producing Bleach Boosters | SQLE, BCHE, CAT | CYP3A4 139/4885MEN1 3318/4885KMT2A 1980/4885 |
| US-20060287210-A1 | Organic catalyst with enhanced enzyme compatibility | AOX1, ACHE, MPO | CYP3A4 101/4885MEN1 2506/4885KMT2A 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.